ACE Inhibitor News and Research RSS Feed - ACE Inhibitor News and Research

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
FDA accepts Symplmed's Prestalia NDA for hypertension treatment

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance. [More]
PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant. [More]
Investigators find effective treatment for life-threatening angioedema attacks in ED

Investigators find effective treatment for life-threatening angioedema attacks in ED

Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department. [More]
Implementation of large-scale hypertension program linked with doubling of hypertension control rates

Implementation of large-scale hypertension program linked with doubling of hypertension control rates

Implementation of a large-scale hypertension program that included evidence-based guidelines and development and sharing of performance metrics was associated with a near-doubling of hypertension control between 2001 and 2009, compared to only modest improvements in state and national control rates, according to a study in the August 21 issue of JAMA. [More]
Soligenix announces personalized medicine collaboration with SciClone

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942. [More]
New survey data reveal need for specialist nurse support in management of patients with heart failure

New survey data reveal need for specialist nurse support in management of patients with heart failure

One year after the publication of the European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012, awareness amongst UK healthcare professionals varies dramatically. [More]
AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes. [More]
Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found. [More]
Ramipril puts spring in step of patients with intermittent claudication

Ramipril puts spring in step of patients with intermittent claudication

Six months of treatment with the angiotensin-converting enzyme inhibitor ramipril produces notable improvements in the walking ability of patients with peripheral artery disease and intermittent claudication, shows a large randomized trial. [More]
Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA. [More]
Dual renin angiotensin system blockade: too many cons

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts. [More]
Hydrogen sulfide may play a wide-ranging role in staving off aging

Hydrogen sulfide may play a wide-ranging role in staving off aging

Hydrogen sulfide (H2S) may play a wide-ranging role in staving off aging, according to a paper published online ahead of print in the journal Molecular and Cellular Biology. [More]
NSAID–antihypertensive combinations may risk kidney damage

NSAID–antihypertensive combinations may risk kidney damage

Physicians should be aware that treating patients with a combination of antihypertensives along with nonsteroidal anti-inflammatory drugs may cause kidney damage, say researchers. [More]
Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive regimens may be preferable to calcium channel blocker-based therapy in patients who are obese, suggest researchers writing in The Lancet. [More]
Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive therapy touted for obese

Diuretic-based antihypertensive regimens may be preferable to calcium channel blocker-based therapy in patients who are obese, suggest researchers writing in The Lancet. [More]
BMI may influence which blood pressure treatments work best

BMI may influence which blood pressure treatments work best

According to new research published Online First in The Lancet, body mass index (BMI) may influence which blood pressure medications work best at reducing the major complications of high blood pressure (strokes, heart attacks, and death). [More]
Dyax second quarter 2012 total revenues increase to $14.0 million

Dyax second quarter 2012 total revenues increase to $14.0 million

Dyax Corp. today announced financial results for the second quarter ended June 30, 2012. [More]
Why is the incidence of gout increasing?

Why is the incidence of gout increasing?

Gout has been described by the Daily Mail as something, “usually associated with port-swilling, over-fed elderly men of the 19th century”. (1) Recent research carried out at the Boston University School of Medicine, however, has found that the incidence of gout in the US is on the rise. (2) Thus, the condition is clearly not something that only affects this stereotype. [More]
Harmonizing prescription drug plans can help save millions of dollars

Harmonizing prescription drug plans can help save millions of dollars

Taxpayers could save millions of dollars if hospitals and provincial governments harmonized their prescription drug plans, new research suggests. [More]

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis. [More]